Organized by First Affiliated Hospital of Zhejiang University School of Medicine, Nature Medicine, Nature Cancer, Nature Reviews Immunology and Nature Reviews Drug Discovery.
Cancer immunotherapy has transformed the therapeutic landscape in oncology, providing durable benefits for patients across a growing number of malignancies. Nevertheless, key challenges remain, including overcoming mechanisms of resistance and tumour heterogeneity, identifying biomarkers of treatment response, and expanding treatment accessibility.
This Nature Conference, organised by editors from Nature Cancer, Nature Medicine, Nature Reviews Drug Discovery and Nature Reviews Immunology, in partnership with Zhejiang University, will bring together leading researchers and clinicians to explore how advances with multiple therapeutic modalities are leading to next-generation drugs that aim to address these challenges.
Attendees will gain a comprehensive view of progress and challenges with therapeutic platforms spanning antibody-based therapies, engineered cell therapies, cancer vaccines and oncolytic viruses, as well as the evolving translational landscape for the overall field. Join a global community of experts to share knowledge, spark collaborations, and accelerate the development of transformative cancer treatments.
Register Now Submit Abstract Deadline: Mar.21, 2027 Contact Us
Event details
Speakers
Patrick Baeuerle
Ludwig Maximilian University of Munich, Germany
- Co-founder, Chief Scientific Advisor and Chairman of the Scientific Advisory Board of Cullinan Therapeutics
- Honorary Professor of Immunology at the Institute for Immunology, Ludwig Maximilian University (LMU), Munich
- As former Executive Partner of venture capital firm MPM BioImpact became the co-founder of eight biotech companies in the US and Europe: Harpoon, Maverick, Werewolf, TCR2, Aktis, Crossbow, iOmx and Cullinan
- Leadership roles in new drug discovery at Tularik, Micromet, Amgen, Harpoon, Maverick, Crossbow and Cullinan
- Pioneering work on T cell-engaging antibodies leading to Blincyto as the first FDA-approved, bispecific, T cell-engaging and CD19-targeting antibody
- Seminal research on transcription factor NF-kappaB
- Formerly Professor and Chairman of Biochemistry and Molecular Biology at the University of Freiburg, School of Medicine, Germany
- Formerly Group Leader at the Gene Center, Martinsried, Germany
- Post Doctorate at the Whitehead Institute/MIT, Cambridge, with David Baltimore
- Study of biochemistry at the Universities of Konstanz and Munich
- Hirsch Index of 146
Chiara Bonini
University Vita-Salute San Raffaele, Italy
Prof. Bonini has received several prestigious awards, including the Young Investigator Award from the American Society of Gene and Cell Therapy (ASGCT, 2005), the Van Bekkum Award from the European Society of Bone Marrow Transplantation (EBMT, 2012, 2016), the Outstanding Achievement Award from the European Society of Gene and Cell Therapy (ESGCT 2024), the Outstanding Achievement Award, NVGCT 2024),the DKMS Mechtild Harf Science Award 2025, Ham Wasserman Lecture at ASH 2025.
She has served on the executive committees of various scientific societies of cell and gene therapy, hematology and stem cell transplantation including ASGCT, ESGCT, EHA and EBMT. Her main research focus is allogeneic stem cell transplantation and the development, preclinical and clinical validation of cell and gene therapy approaches to treat cancer. Her scientific production includes > 200 papers in international scientific journals, >10 international patents. She has been Invited speaker at > 230 International Meetings, Workshops and Universities.
Christian Buchholz
Paul-Ehrlich-Institut, Germany
Christian Buchholz heads the Section of Molecular Biotechnology and Gene Therapy at the Paul-Ehrlich-Institut and is Associate Professor for Biochemistry at the Goethe-University in Frankfurt. Being for more than 20 years active in the field, his research focusses on the engineering of gene transfer vectors to understand their cell entry and improve their applicability in molecular medicine. Making use of T-cell targeted vectors his team provided proof-of-principle for in vivo generated human CAR T cells.
Paul J. Carter
Genentech, USA
Paul J. Carter, PhD, is a Genentech Fellow in the Antibody Engineering Department at Genentech, Inc. In 2022, he was elected to the US National Academy of Engineering “for creating novel approaches to discovering and developing life-saving antibody therapeutics, including bispecific antibodies.” Carter co-invented antibody humanization technology used at Genentech to design nine approved antibody therapeutics that have been administered to more than 10 million patients worldwide. He and his collaborators also invented knobs-into-holes and common light chain technologies used by multiple companies in the design of seven approved bispecific antibodies.
Carter has 40 years of biotechnology experience, including more than 30 years at Genentech. His current research focuses on understanding antibody self-interactions at high concentrations to facilitate the engineering of antibodies suitable for subcutaneous delivery. Additionally, he researches nonclinical immunogenicity risk assessment and mitigation for antibody therapeutics. He is an inventor or co-inventor on 54 issued US patents and an author or co-author of more than 125 scientific publications, cited more than 30,000 times. Carter received his BA in Natural Sciences from Cambridge University and his PhD under Sir Greg Winter at the MRC Laboratory of Molecular Biology in Cambridge, followed by postdoctoral training with Dr. James Wells at Genentech.
Sarat Chandarlapaty
Memorial Sloan Kettering, USA
Sarat Chandarlapaty is a Physician-Scientist at Memorial Sloan Kettering in New York where he holds the Naddisy Foundation Endowed Chair in Breast Cancer Research. Sarat completed a PhD in Biochemistry from UNC and his MD from Wake Forest University. He went on to residency and fellowship in Oncology at MSK, performing postdoctoral studies in the lab of Neal Rosen.
Sarat has focused his independent research career on understanding the basis for resistance to targeted therapies in cancer. His laboratory discovered and helped characterize mutation in ESR1 as the dominant, acquired mechanism of clinical resistance to aromatase inhibitors and developed oral ER antagonists as modality to overcome resistance. His group has gone on to characterize major forms of resistance to targeted therapies including CDK4/6, PI3K/AKT, and HER2 inhibitors. In recent years his group has investigated mechanisms of resistance to Antibody Drug Conjugates and new strategies to optimize their use.
Antonio Chiocca
Harvard Medical School, USA
Dr. E. Antonio (‘Nino”) Chiocca was born in the city of Padova in northeastern Italy. In 1979, he came to the USA where he attended college at the University of Texas at El Paso, where he graduated with a BS in 1982. His interest in biomedical research was solidified by an undergraduate research project that he attended at MD Anderson Hospital in the summer of 1981. He entered the MD/PhD program offered by the University of Texas Medical School at Houston and the Graduate School of Biomedical Sciences. In 2004, he became the first Chairman of the newly instituted Department of Neurological Surgery at the Ohio State University Medical Center, where he held the Dardinger Family Endowed Chair in Oncological Neurosurgery. In 2012, he became the Chairman of the Department of Neurosurgery at Brigham & Women's Hospital, now Mass General Brigham, and the Harvey W. Cushing Professor of Neurosurgery at Harvard Medical School, funded by the Daniel E. Ponton fund. In addition to being the Chair, Dr. Chiocca is the Co-Chair of the Executive Committee in the Mass General Brigham Cancer Institute (MGB CI), Executive Director for the Center for Tumors of the Nervous System (CTNS) in the MGB CI, and is a member of the Neuroscience Institute (NSI).
Dr. Chiocca is a clinician-scientist whose research is focused on developing novel genetic therapies for malignant brain tumors. He is the current President of the American Association of Neurological Surgeons and the past president of the Society for Neuro-oncology, American Academy of Neurological Surgery, and the Society of Neurological Surgeons.
Elena Garralda Cabanas
Vall d'Hebron Institute of Oncology (VHIO), Spain
Vall d'Hebron University Hospital (HUVH), Spain
Elena Garralda, MD PhD is a Medical Oncologist, Principal Investigator and Researcher.
Currently serving as Director of the Molecular Cancer Therapy Research Unit (UITM) – CaixaResearch, Co-Director of the Clinical Research Program and Head of the Early Drug Development at VHIO.
Dedicated to translational research, she coordinates the phase I program and the clinical research program, where complex clinical trials with drugs in early development (phase I and early phase II) focus on targeted agents and immunotherapies.
Her work specially emphasizes immuno-oncology and first-in-human studies of targeted therapies, rational combinations, and biomarker-driven trials.
She actively integrates genomic profiling and immunological insights to guide biomarker-driven treatment strategies, and she is widely recognized for her expertise in early-phase clinical trials and for pioneering the implementation of next-generation cell therapies, including tumor-infiltrating lymphocytes (TILs) targeting neo-antigens in tumors resistant to checkpoint inhibitors.
Dr Garralda is PI on several EU-funded projects (e.g., CCE-DART, PCM4EU) focused on delivering personalized cancer care across Europe.
She is chair of EORTC’s RECIST Task Force, Chair of the Methodology for the Development of Innovative Cancer Therapies (MDICT 2025), member of ENA’s Scientific Committee and usually serves as faculty of the “Methods in Clinical Cancer Research” annual workshop, as Faculty at ESMO and as member or chair of several working groups, associations and Scientific Committees.
She has authored over 150 articles published in peer-reviewed journals including Journal of Clinical Oncology, Nature Medicine and New England Journal of Medicine, has presented more than 200 abstracts and posters in international congresses such as AACR, ESMO, ASCO, TAT or ENA, and serves as reviewer for JAMA Oncology, Annals of Oncology, Cancer Treatment Reviews, British Journal of Cancer, Clinical Cancer Research, Lancet Oncology, or Nature Reviews. She has been Section Editor for Molecular Oncology and European Journal of Cancer and is now an Associate Editor for ESMO Open
Hans-Peter Gerber
Sutro Biopharma, Inc., USA
Hans-Peter Gerber, Ph.D., has served as Chief Scientific Officer of Sutro since September 2023, bringing more than three decades experience in advancing transformative biologics in oncology, with deep expertise in antibody-drug conjugates (ADCs), redirected T-cell engagers, and cell-based immunotherapies.
Prior to Sutro, Hans-Peter co-founded Codeable Therapeutics in 2022 to advance next-generation ADCs engineered to elicit immunogenic cell death and deepen antitumor immune responses. He also served as Chief Scientific Officer at 3T Biosciences, where he completed an oversubscribed Series A while serving as interim Chief Executive Officer. Previously, Hans-Peter built the R&D organization at Maverick Therapeutics, leading to its acquisition by Takeda in 2021, and served as an independent director at NBE Therapeutics, acquired by Boehringer Ingelheim in 2021.
Earlier in his career, he held scientific leadership roles at Genentech, Seattle Genetics, and Pfizer, overseeing multiple oncology programs from discovery through IND submission. His work contributed to more than 10 IND filings, including seven ADCs, and to three BLAs, including Avastin®, Mylotarg®, and Besponsa®.
An internationally recognized leader in oncology R&D, Hans-Peter has authored over 100 peer-reviewed publications, holds over 100 patents, and has contributed to the development of six FDA-approved ADCs. He also serves as Chairman of the Board at T-CURX in Germany and as a board member at Athebio in Switzerland. Hans-Peter received his M.S. in Biochemistry and Ph.D. in Molecular Biology from the University of Zurich, Switzerland.
Misty Jenkins
Walter and Eliza Hall Institute of Medical Research, Australia
Eleni Lagkadinou
AbbVie, USA
Dr. Eleni Lagkadinou serves as Vice President and Head of Oncology Early Development at AbbVie, leading a cross-functional team dedicated to rapidly advancing early-stage R&D in oncology.
With more than 25 years of experience spanning clinical medicine and biopharma, she brings deep scientific expertise and strategic leadership to AbbVie’s oncology pipeline.
Prior to joining AbbVie, Dr. Lagkadinou held senior roles at Roche Pharma AG and at BioNTech SE, where she contributed to the clinical development and regulatory approval of the Pfizer-BioNTech COVID-19 vaccine, and at Bayer Pharmaceuticals. Her career is defined by a commitment to translating scientific innovation into therapies that make a meaningful difference for patients with cancer and other serious illnesses.
Tingbo LIANG
The First Affiliated Hospital, Zhejiang University School of Medicine, China
LIANG Tingbo, MD, PhD丨Professor, Chief Physician, Doctoral Advisor
President of The First Affiliated Hospital, Zhejiang University School of Medicine; Changjiang Distinguished Scholar by the Ministry of Education; Distinguished Young Scholar of the National Natural Science Foundation of China; recipient of the Ho Leung Ho Lee Science and Technology Progress Award, Bethune Medal, National Innovation Pioneer Award, National May 1st Labor Medal, Tan Jiazhen Life Science Award, Wu Jieping – Paul Janssen Medical and Pharmaceutical Award; Zhejiang Top-level Expert.
- Fellow, American College of Surgeons (FACS)
- Fellow, American Institute for Medical and Biological Engineering (AIMBE Fellow)
- Vice President of Chinese Research Hospital Association and Chair of its Society of Enhanced Recovery After Surgery
- Member, Pancreatic Surgery Subgroup, Society of Surgery, Chinese Medical Association
- Vice Chair, Professional Committee of Pancreatic Diseases, Chinese Medical Doctor Association
- Vice Chair, Professional Committee of Biliary Tract Tumor, China Anti-Cancer Association
- Vice President, Zhejiang Hospital Association
- Vice President, Zhejiang Medical Association
- Chair, Professional Committee of Pancreatic Diseases, Zhejiang Medical Doctor Association
- Director, Zhejiang Key Laboratory of Pancreatic Disease
- Director, Joint International Laboratory of Pancreatic Diseases of the Ministry of Education
He has led over 30 research projects including the 863 Program of the Ministry of Science and Technology, Key Program of the National Natural Science Foundation of China, National Key Research and Development Program, etc. He has published over 300 SCI-indexed papers as the first or corresponding author. He received one Second Prize of the National Science and Technology Progress Award as a principal contributor and six provincial- or ministerial-level First Prizes as the first contributor.
Marcela Maus
Harvard Medical School, USA
Marcela Maus, M.D., Ph.D., is a Professor of Medicine at Harvard Medical School, the Paula O’Keeffe Chair in Oncology, and Director of Cellular Immunotherapy at The Krantz Family Center for Cancer Research, Mass General Brigham Cancer Institute. She is an internationally recognized translational physician-scientist specializing in T-cell and cellular immunotherapies for cancer, with over 230 publications and multiple NIH grants. Her research focuses on human T-cell biology and the clinical translation of engineered T-cell therapies. Dr. Maus trained at MIT, the University of Pennsylvania, and Memorial Sloan Kettering Cancer Center.
Ignacio Melero
University of Navarra, Spain
Ignacio Melero, MD, PhD, is Professor of Immunology at the University of Navarra, Senior Group Leader at Cima Universidad de Navarra, Co-Director of the Department of Immunology and Immunotherapy, and Kidani Chair of Oncology at the University of Oxford. Over the past three decades, he has established an internationally recognised translational research programme dedicated to understanding how antitumour immunity can be therapeutically generated, amplified, sustained and restored.
Professor Melero is internationally recognised for pioneering the therapeutic development of CD137 (4-1BB) costimulation, from the original proof-of-concept demonstrating tumour rejection with agonistic antibodies to the mechanistic foundations of current tumour-targeted and bispecific CD137 immunotherapies. His research has also defined key mechanisms governing dendritic cell–T-cell interactions, immune resistance to checkpoint blockade, and the clinical translation of immunotherapy for hepatocellular carcinoma. His work continues to shape the development of next-generation antibody-based cancer immunotherapies by integrating fundamental immunology with clinical translation.
Ira Mellman
Parker Institute for Cancer Immunotherapy and Medici Therapeutics, USA
Ira Mellman (FAACR, FAIO) is President of Research at the Parker Institute of Cancer Immunotherapy (PICI) and CSO of Medici Therapeutics, both in San Francisco, California. An expert in cancer vaccines, Ira is a member of the US National Academy of Sciences and former VP of Cancer Immunology at Genentech, Sterling Professor of Cell Biology & Immunobiology at Yale Medical School, and a postdoctoral fellow with Ralph Steinman at The Rockefeller University. Ira is best known for fundamental advances in cell biology and immunology (particularly the discovery of endosomes) and for applying these insights to elucidate the mechanisms of antigen processing by dendritic cells and the basis of PD-1/PD-L1 inhibition; Ira was also responsible for devising the Cancer Immunity Cycle framework. At Genentech, his group discovered or developed four FDA-approved cancer agents, including the anti-PD-L1 antibody atezolizumab (Tecentriq®); he is also credited with initiating the first personalized mRNA cancer vaccine in collaboration with BioNTech and Memorial Sloan Kettering Cancer Center. Ira is the recipient of the 2025 Richard Smalley award of the Society for the Immunotherapy of Cancer and the Lloyd J. Old Award for Cancer Immunotherapy from the American Association for Cancer Research.
Patrick Ott
Dana Farber Cancer Institute, USA
Patrick Ott is the Director of the Center for Cancer Vaccines and the Clinical Director of the Melanoma Center at Dana Farber Cancer Institute. His primary research interests are in melanoma and immunotherapy, specifically the development of innovative tumor vaccine approaches. Dr. Ott led several of the earliest clinical trials testing personalized neoantigen vaccines in patients with cancer. These studies are widely considered pioneering work for the therapeutic area of personalized neoantigen cancer vaccines and provided the rationale for randomized clinical trials in patients with melanoma and other cancers. As IND holder for a personalized multi-peptide vaccine targeting patient tumor-specific neoantigens (NeoVax) Dr. Ott oversees a portfolio of investigator-initiated phase 1 clinical trials testing these vaccines in patients with melanoma and other solid and hematological malignancies.
Katy Rezvani
Professor of Medicine
The University of Texas MD Anderson Cancer Center, Texas, USA
Katy Rezvani, MD, PhD is a professor of medicine at the University of Texas MD Anderson Cancer Center, where she serves as the Vice President & Head, Cell Therapy Institute for Discovery and Innovation, Barnts Family Distinguished Chair for Cancer Research, and medical director of the GMP Facility. She leads a research lab with a focus on NK cell biology and developing novel NK cell engineering strategies for cancer, with the aim of translating these discoveries to the clinic. Dr. Rezvani completed her medical training at University College London, England and her PhD at Imperial College London. She completed her training in immunology and transplantation biology at the National Institutes of Health, Bethesda, MD. In addition, she has co-authored over 250 peer-reviewed publications and received multiple prizes and awards, including the American Society of Hematology E. Donnall Thomas award.
Feng Shao
National Institute of Biological Sciences (NIBS), Beijing, China
Dr. Feng Shao is an investigator and deputy director at National Institute of Biological Sciences (NIBS), Beijing. He was a chemistry undergraduate of Peking University and obtained his PhD from University of Michigan. Before returning to China in 2005 to assume an assistant investigator at NIBS, he was a Damon Runyon Postdoc Research Fellow at Harvard Medical School. Dr. Shao has been appointed as an Endowed Chair Professor of Tsinghua University since 2020 and currently also serves as the Associate Director of Changping National Laboratory and the President of Chinese Society of Biochemistry and Molecular Biology.
Dr. Shao’s research lies at the interface between bacterial pathogen and host immunity. He identified most of the known cytosolic receptors for bacteria, including caspase-11/4/5 for LPS and ALPK1 for ADP-heptose in LPS biosynthesis. He identified gasdermin-D whose cleavage by caspase-1/4/5/11 determines pyroptosis, critical for sepsis and other inflammatory diseases. His work establishes the gasdermin family of pore-forming proteins, re-defining pyroptosis as gasdermin-mediated programmed necrosis.
Dr. Shao has published >100 peer-reviewed articles with the total citation of > 70,000 and an H index of 82. His work has been recognized by numerous awards including the Future Science Prize, William B. Coley Award for Distinguished Research in Basic and Tumor Immunology, HHMI International Early Career Award and the Protein Society Irving Sigal Young Investigator Award. He is an elected member of the Chinese Academy of Sciences and the German National Academy of Sciences Leopoldina, an associate member of EMBO, and a fellow of American Academy of Microbiology and Chinese Academy of Medical Sciences.
Lillian L. Siu
University of Toronto, Canada
Inge Marie Svane
Copenhagen University Hospital, Herlev, Denmark
Inge Marie Svane, MD, PhD is Professor in Clinical Cancer Immune Therapy at the University of Copenhagen, Director of National Center for Cancer Immune Therapy (CCIT-DK), Herlev and Gentofte Hospital, and Chief Physician specialized in melanoma at the Department of Oncology at Copenhagen University Hospital, Herlev, Denmark.
Inge Marie Svane has more than 25 years of research experience in cancer immunology and immunotherapy and holds a PhD in basic cancer immunology. She has pioneered the field of cancer immunotherapy in Denmark, building up CCIT-DK, a translational research center in a leading European position. Her focus of expertise is T-cell based adoptive cell therapy and other cellular therapies, cancer vaccines, and immune regulation.
Since 2001 she has initiated more than 30 phase I, II, and III trials as academic sponsor within the area of immunotherapy.
Inge Marie Svane is co-author of more than 350 scientific publications.
Özlem Türeci
BioNTech SE, Germany
Xiawei WEI
West China Hospital, Sichuan University, China
Neeha Zaidi
Johns Hopkins School of Medicine, USA
Hongyun Zhao
Sun Yat-sen University Cancer Center, China
Hongyun Zhao, PhD, is a oncologist and Professor at Sun Yat-sen University Cancer Center, where she serves as Chief Physician, PhD supervisor, Director of the Phase I Unit, and Deputy Director of the Department of Clinical Trial Center. With training in oncology at Sun Yat-sen University and visiting scholarship at MD Anderson Cancer Center, she has become a leading figure in precision therapy and innovative drug development for lung cancer. Zhao has spearheaded first-in-human trials of groundbreaking agents such as EGFR/HER3 bispecific ADC, B7-H3 ADC, and ROS1 TKI, many of which progressed to Phase III studies and reshaped global treatment guidelines. Her work has led to landmark publications in Nature Medicine, Lancet Oncology, and Cancer Cell. As principal investigator of major national grants, she has advanced translational strategies to overcome drug resistance. With over 80 SCI papers and multiple national awards, Zhao has established China’s most influential Phase I oncology ward.